Business Wire

CHUGAI-PHARMACEUTICAL

4.2.2019 02:02:14 CET | Business Wire | Press release

Share
Chugai’s Hemlibra® Gains Positive CHMP Opinion in Severe Hemophilia A Without Inhibitors

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that Roche has received notification that the EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Hemlibra® , a treatment for hemophilia A created by Chugai, for routine prophylaxis of bleeding episodes in adults and children with severe hemophilia A without factor VIII inhibitors, administered once weekly, every two weeks, or every four weeks. The CHMP has also adopted a positive opinion for additional dosing options of every two weeks or every four weeks in adults and children with hemophilia A with factor VIII inhibitors.

“We are thrilled that Hemlibra is expected to be approved shortly for people with severe hemophilia A without inhibitors in the Europe Union (EU). Also, I’m very pleased that people in the EU with hemophilia A will soon be offered multiple options of Hemlibra’s dosing interval regardless of their inhibitor expression,” said Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit, Dr. Osamu Okuda. “Hemlibra is co-promoted by Chugai and Roche in Germany, France, and the United Kingdom, as is the case with the anti-rheumatic agent RoActemra® . We are committed to pursue our efforts in collaboration with Roche so that Hemlibra may further contribute to the treatment of hemophilia A.”

This positive opinion is based on results from two Phase III studies HAVEN 3 (NCT02847637) and HAVEN 4 (NCT03020160), conducted jointly with Roche and Genentech. HAVEN 3 study was conducted to evaluate the reduction of bleed rate of Hemlibra subcutaneous injection once a week and once every two weeks in people with hemophilia A (12 years of age or older) without inhibitors to factor VIII. HAVEN 4 study was conducted to evaluate efficacy, safety, and pharmacokinetics of Hemlibra subcutaneous injection every four weeks in people with hemophilia A (12 years of age or older), with and without inhibitors to factor VIII.

In Japan, Chugai obtained regulatory approval for Hemlibra from the Ministry of Health, Labour and Welfare in December 2018 for an additional indication of prophylactic treatment for people with hemophilia A without inhibitors to factor VIII, as well as for additional dosage and administration as a biweekly or every four-week treatment for people with hemophilia A with inhibitors to factor VIII.

References

Chugai’s HEMLIBRA® Receives Regulatory Approval from U.S. FDA for Hemophilia A without Inhibitors
Press release issued on October 5, 2018
https://www.chugai-pharm.co.jp/english/news/detail/20181005100000_553.html

Chugai’s HEMLIBRA® Subcutaneous Injection Receives Approval for Hemophilia A without Inhibitors and Extension of Dosing Interval -- HEMLIBRA is now available for Hemophilia A, regardless of inhibitor status –
Press release issued on December 21, 2018
https://www.chugai-pharm.co.jp/english/news/detail/20181221153002_580.html

About Severe Hemophilia A

People with severe hemophilia A is defined as the condition with less than 1 % of factor VIII levels. Hemophilia A affects around 320,000 people worldwide, 1,2 approximately 50-60% of whom are expected to have a severe form of the disorder3 .

1) WFH. Guidelines for the management of haemophilia. 2012 [Internet; cited 2018 July]. Available from:
http://www1.wfh.org/publications/files/pdf-1472.pdf . (as of February 1, 2019)
2) Berntorp E, Shapiro AD. Modern haemophilia care. The Lancet 2012; 370:1447-1456.
3) Marder VJ, et al. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. 6th Edition, 2013. Milwakee, Wisconsin. Lippincott Williams and Wilkin.

About Chugai

Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area.
Additional information is available on the internet at https://www.chugai-pharm.co.jp/english . 

Trademarks used or mentioned in this release are protected by law.

Contact:

For Media Chugai Pharmaceutical Co., Ltd. Media Relations Group, Corporate Communications Dept., Tomoko Shimizu Tel: +81-3-3273-0881 E-mail: pr@chugai-pharm.co.jp

For US media Chugai Pharma USA Inc. Casey Astringer Tel: +1-908-516-1350 E-mail: pr@chugai-pharm.com

For European media Chugai Pharma France SAS Nathalie Leroy Tel: +33-1-56-37-05-21 E-mail: pr@chugai.eu

For Taiwanese media Chugai Pharma Taiwan Ltd. Susan Chou Tel: +886-2-2715-2000 E-mail: pr@chugai.com.tw

For Investors Chugai Pharmaceutical Co., Ltd. Investor Relations Group, Corporate Communications Dept., Toshiya Sasai Tel: +81-3-3273-0554 E-mail: ir@chugai-pharm.co.jp

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Persona Earns CEN/TS 18099 High Certification for Injection Attack Detection21.11.2026 15:30:00 CET | Press release

Independent evaluation of Persona's Android SDK confirms defenses against deepfakes and other injected media at the top level of the first standard Persona, the leading global identity platform, today announced that its Android SDK has earned CEN/TS 18099 High certification for injection attack detection (IAD). High certification is the top level of the European standard. The evaluation was run by CLR CERT, the certification body of Cabinet Louis Reynaud (CLR) Labs. CLR Labs is accredited under ISO/IEC 17025, the international standard for testing laboratories, and it edits CEN/TS 18099. This certificated injection attack detection is available to all Persona customers and can be activated by working with Persona's team. Injection attacks skip the camera entirely. Instead of holding a photo or mask up to a lens, fraudsters use virtual cameras, emulators and tampered devices to feed stolen, manipulated, or AI-generated media straight into the verification flow. To the system, the result

Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 22:30:00 CET | Press release

Proposed facilitation of China Resources’ exit from Oatly requires a tender offer because of Swedish law requirements Verlinvest recommends that Oatly shareholders and holders of ADSs do not tender their shares or ADSs. Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement

Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 20:54:00 CET | Press release

With Picsart Platform, developers can build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. Key Takeaways One bundle, four ways to build: the API, the CLI, a playground to test models, and Picsart Media Studio, an MCP server that works with compatible AI assistants. One integration for image, video, audio and text generation from 250+ models across 30+ providers, with the freedom to switch models as a product evolves. Self-serve users pay per generation at competitive, published rates. Developers get access to Picsart's proprietary editing models, like Enhance and background removal, which are only available on Picsart Platform. Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 mil

NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release

The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e

Frontgrade Technologies Help Power Critical Computing and Electronics Aboard NASA’s Roman Space Telescope20.11.2026 18:40:00 CET | Press release

Frontgrade processors and radiation-hardened microelectronics support critical spacecraft and instrument functions on NASA’s flagship astrophysics mission Frontgrade today announced that technologies from across its space electronics portfolio are supporting multiple mission-critical systems aboard NASA’s Nancy Grace Roman Space Telescope, which successfully launched on August 30, 2026. Roman is NASA’s flagship astrophysics observatory designed to investigate dark energy, discover exoplanets and explore the evolution of the universe. Its onboard electronics include radiation-hardened processors and microelectronics, providing critical processing, communications, power-management and control functions across the spacecraft. At the centre of Roman’s computing architecture are Frontgrade Gaisler’s GR740 and GR712RC processors. The GR740 radiation-hardened quad-core LEON4FT processor serves as the computing engine for the Wildcat Processor Card, used in the spacecraft’s primary and redunda

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye